Experimental drug shows promise for rare HIV-Linked cancer
NCT ID NCT05646082
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests the safety of dostarlimab, an immunotherapy drug, in people with HIV-related Kaposi sarcoma that hasn't responded to standard HIV treatment. About 15-20 participants will receive the drug alongside their HIV therapy. The goal is to see if the drug is safe and can help the immune system fight the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HIV ASSOCIATED KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chelsea & Westminster Hospital
London, SW10 9NH, United Kingdom